Herein, most symptoms appeared within 7 days from treatment initiation (50.0 and 77.3% in the control and preexisting proteinuria groups, respectively), suggesting that symptom occurs earlier than that with other anti-VEGF treatments for renal cell and hepatocellular carcinoma and lung cancer13–16. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.